Clinical trial
Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive…
NCT00238290 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00238290 |
|---|---|
| Title | Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer |
| Official title | Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab + Letrozole |
| Enrollment | 13 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2010 |
| Completion | Apr 1, 2011 |
| First posted | Oct 13, 2005 |
| Last update posted | May 15, 2019 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: